|
|
- Articoli in Inglese già pubblicati
2001 2002 2003 2004
- Articoli 2005:
1.
Messori A, Orsi C, Cecchi M, Vaiani
M.
Off-label
prescriptions in oncology: economic implications and practical solutions. 10 May 2005
http://bmj.com/cgi/eletters/330/7494/746-b
- 106386,
- Santarlasci B,Trippoli
S, Messori A. Valuing clinical benefits: different
price estimates for ICDs. http://bmj.com/cgi/eletters/325/7372/1050#107375,
20 May 2005
- Messori A, Trippoli S, Burchini G, Orsi
C, Santarlasci B. Orphan drugs: how can equity and
“pure” cost-effectiveness be adjusted for the size of the national
drug market? http://bmj.com/cgi/eletters/331/7523/1016#120619,
3 Nov 2005
- Messori A, Orsi C, Cecchi M, Vaiani M. Off-label
prescriptions in oncology: economic implications and practical
solutions. http://bmj.com/cgi/eletters/330/7494/746-b#106386,
10 May 2005
- Messori A, Trippoli S, Santarlasci B. Negotiating the
price of innovative treatments based on cost-effectiveness techniques. http://bmj.com/cgi/eletters/330/7482/65#92665,
14 Jan 2005
- Cecchi M, Caccese E, Vaiani M, Tendi E. Lowering trastuzumab price to account for the potential
increase in its market. http://bmj.com/cgi/eletters/331/7524/1035#120669,
4 Nov 2005
- Cecchi M, Caccese E, Messori A. Bortezomib
in multiple myeloma. N
Engl J Med. 2005 22;353(12):1297-8
Articoli recenti:
Zaccara G, Messori A, Cincotta
M, Burchini G. Comparison of the efficacy and
tolerability of new antiepileptic drugs: what can we learn from long-term
studies? Acta Neurol
Scand 2006: DOI: 10.1111/j.1600-0404.2006.00705. in press
|
|
|